Drugs / EGFRBi-Armed Autologous T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02521090 | Aug 2015 → Mar 2016 | adult glioblastoma, gliosarcoma | Barbara Ann Karmanos Cancer Institute | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGFRBi-Armed Autologous T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02521090 ↗ |
| Action | Deplete | “seek out, attach to, and destroy glioblastoma cells” NCT02521090 ↗ |
| Modality | Cell therapy | “EGFRBi-armed autologous T cells” NCT02521090 ↗ |
| Route | Intrathecal | “intrathecal (IT) injections” NCT02521090 ↗ |
| Target | EGFR | “anti-EGFR bispecific antibody” NCT02521090 ↗ |